// App-Quantinova.ai

: Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Researchers

Presenter

  • Paolo Caimi

Principal Investigators

  • Brad S. Kahl

  • Mehdi Hamadani

  • Carmelo Carlo-Stella

  • Shui He

  • David Ungar

  • Jay Feingold

  • Kirit M. Ardeshna

  • John Radford

  • Melhem Solh

  • Leonard Heffner

  • Owen A. O'Connor

Medical Centers

  • Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH

  • Siteman Cancer Center, Washington University, Saint Louis, MO

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

  • Senology Unit, Humanitas Cancer Center, Rozzano, Italy

  • ADC Therapeutics America, Inc, Murray Hill

  • ADC Therapeutics America, Inc, Murray Hill

  • ADC Therapeutics America, Inc, Murray Hill

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

  • Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY

Locations

  • United States

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Single Arm

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved